[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349692-105":59,"doc-detail-349692-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","statin-dye-conjugates-for-selective-targeting-of-kras-mutant-cancer-cells","Statin-dye conjugates for selective targeting of KRAS mutant cancer cells","","Pancreatic ductal adenocarcinoma (PDAC) is frequently driven by KRAS mutations, yet treatment options remain limited. This study synthesizes statin-dye conjugates by attaching a fluorescent Cy5.5 dye to simvastatin and pravastatin to test whether selective uptake occurs in KRAS mutant cells. The conjugates show enhanced uptake in KRASMUT cells versus KRAS wild-type cells, with KRASMUT cells taking up statin-Cy5.5 via increased macropinocytosis. In an engineered co-culture PDAC model, pravastatin-Cy5.5 selectively kills KRASMUT cancer cells without harming KRAS wild-type CAFs.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/statin-dye-conjugates-for-selective-targeting-of-kras-mutant-cancer-cells/349692/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/statin-dye-conjugates-for-selective-targeting-of-kras-mutant-cancer-cells/349692.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-09","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are KRAS mutations important in PDAC treatment?","Question",{"text":113,"@type":114},"Over 90% of PDAC patients involve KRAS mutations, which drive tumorigenesis and are associated with limited effectiveness of current therapies.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were the statin-dye conjugates designed?",{"text":118,"@type":114},"The study attaches a fluorescent dye (Cy5.5) to two statins—simvastatin and pravastatin—to create conjugates for uptake and targeting studies.",{"name":120,"@type":111,"acceptedAnswer":121},"What evidence supports selective targeting of KRASMUT cells?",{"text":122,"@type":114},"Statin-Cy5.5 conjugates show markedly enhanced uptake in KRASMUT cells compared with KRAS wild-type cells, and the pravastatin-Cy5.5 conjugate selectively kills KRASMUT pancreatic cancer cells in a co-culture model.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},349692,1790167894,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","OPEN ACCESS  \nCitation: Moon H-r, Cai Z, Cho BK,  \nChang H, Hong ST, Zhao JJ, et al. (2026) Statin-dye conjugates for selective targeting of KRAS mutant cancer cells. PLoS One 21(1): e0340189. [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0340189  \nEditor: Luca Pesce, Università di Pisa: Universita degli Studi di Pisa, ITALY  \nReceived: April 24, 2025  \nAccepted: December 17, 2025  \nPublished: January 9, 2026  \nCopyright: © 2026 Moon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData availability statement: All relevant data underlying the results are included in the paper and its Supporting Information files. The minimal data set required to replicate the findings is provided.  \nFunding: This work was supported by the Intramural Research Program of KIST and the  \nRESEARCH ARTICLE  \nStatin-dye conjugates for selective targeting of KRAS mutant cancer cells  \nHye-ran Moon1,2☯, Zhenying Cai3☯, Bo Kyung Cho4☯, Hyeyoun Chang3,4, Seung Taek Hong4,5, Jean J. Zhao3, Ick Chan Kwon3,4,6, Thomas M. Roberts3*, Bumsoo Han1,7,8,9*, Ju Hee Ryu4,6*  \n1 School of Mechanical Engineering, Purdue University, West Lafayette, Indiana, United States of America, 2 School of Integrative Engineering, Chung-Ang University, Seoul, Republic of Korea,  \n3 Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America, 4 Medicinal Materials Research Center, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea, 5 Division of Biohealthcare, Department of Echo-Applied Chemistry, Daejin University, Gyeonggi-do, Republic of Korea, 6 KU-KIST Graduate School of Converging Science and Technology, KIST school, University of Science and Technology, Seoul, Republic of Korea, 7 Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana, United States of America, 8 Department of Mechanical Science and Engineering, Materials Research Laboratory and Cancer Center at Illinois, University of Illinois Urbana-Champaign, Urbana, Illinois, United States of America, 9 Chan Zuckerberg Biohub Chicago, Chicago, Illinois, United States of America  \n☯ These authors contributed equally to this work.  \n* [Thomas_Roberts@dfci.harvard.edu](Thomas_Roberts@dfci.harvard.edu) (TMR); [bumsooh@illinois.edu](bumsooh@illinois.edu) (BH); [jhryu@kist.re.kr](jhryu@kist.re.kr) (JHR)  \nAbstract  \nOver 90% of pancreatic ductal adenocarcinoma (PDAC) patients involve KRAS mutations (KRASMUT), for which current treatment options are limited. Statins, commonly used to lower cholesterol, have demonstrated certain selective toxicity towards KRAS-transformed cells, prompting the question of whether statin-based conjugates could achieve selective uptake specifically in KRASMUT cells. To investigate this, we synthesized statin-dye conjugates by attaching a fluorescent dye (Cy5 .5) to two statins: simvastatin and pravastatin, aiming to assess whether selective uptake indeed occurs. Our findings revealed that these conjugates exhibited markedly enhanced uptake in KRASMUT cells compared to KRAS wild-type (KRASWT) cells. We evaluated the uptake of these conjugates in both KRASMUT and KRASWT cells and examined their potential to selectively target KRASMUT pancreatic cancer cells (PCCs) using an engineered PDAC tumor model co-cultured with PCCs and  \ncancer-associated fibroblasts (CAFs) . Our findings indicate that KRASMUT cancer cells exhibited higher uptake of statin-Cy5 .5 conjugates via enhanced macropinocytosis compared to KRASWT cancer cells and CAFs. We also found enhanced uptake of the statin-Cy5 .5 conjugate in MCF10A cells with PTEN deficiency, a condition known to elevate macropinocytosis, compared to control MCF10A cells with wild-type PTEN.","cbCaijTk4AsMHdNT","https://ap.wps.com/l/cbCaijTk4AsMHdNT","pdf",1497677,18,"English","# Abstract\n## KRAS mutation-driven PDAC background\n## Design and synthesis of statin-Cy5.5 conjugates\n## Selective uptake in KRASMUT vs KRASWT cells\n## Mechanism: enhanced macropinocytosis\n## Selective killing in tumor co-culture model","[{\"question\":\"Why are KRAS mutations important in PDAC treatment?\",\"answer\":\"Over 90% of PDAC patients involve KRAS mutations, which drive tumorigenesis and are associated with limited effectiveness of current therapies.\"},{\"question\":\"How were the statin-dye conjugates designed?\",\"answer\":\"The study attaches a fluorescent dye (Cy5.5) to two statins—simvastatin and pravastatin—to create conjugates for uptake and targeting studies.\"},{\"question\":\"What evidence supports selective targeting of KRASMUT cells?\",\"answer\":\"Statin-Cy5.5 conjugates show markedly enhanced uptake in KRASMUT cells compared with KRAS wild-type cells, and the pravastatin-Cy5.5 conjugate selectively kills KRASMUT pancreatic cancer cells in a co-culture model.\"}]","Statin-dye conjugates for selective targeting of KRAS mutant cancer cells | PDF",1790085080,45,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eac713727c01d3f599ffe757043a28b3.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de13e0a2070668544d4247e3339f8097.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2fbd01555df13cbd9b4f497a0a3aa4f2.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/029e6e2c165978094bd156053fd68c49.webp",980,1268]